All In Biotech

Drug Trial Radar · NCT06335979

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Oct 8, 2024

Primary completion

Nov 17, 2027

Study completion Nov 17, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE

Conditions

  • Systemic Lupus Erythematosus, SLE

Interventions

  • PIT565Drug

    In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: From Study Day 1 until Study Day 180

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Leiden, South Holland, Netherlands

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.